Wedbush Bullish on Black Diamond Therapeutics (BDTX) Following Progress in Silevertinib Program
As of March 17, 2026, Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics Inc. (BDTX)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Leucadia National Ian Cumming And Joseph Steinberg | 16,208 | $34,523 | -26% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.34 | 400,000 | $934,080.00 | 8,517,839 | 2023-10-17 | Filing | |
| $5.00 | 935,850 | $4,679,250.00 | 3,213,828 | 2023-07-05 | Filing | |
| $5.00 | 1,000,000 | $5,000,000.00 | 4,448,757 | 2023-07-05 | Filing | |
| $5.00 | 1,000,000 | $5,000,000.00 | 8,117,839 | 2023-06-30 | Filing | |
| $5.49 | 1,740,000 | $9,555,036.00 | 7,117,839 | 2023-06-27 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.12 | 500,000 | $1,058,450.00 | 2,733,547 | 2025-03-19 | Filing | |
| $1.95 | 584,292 | $1,141,239.13 | 3,233,547 | 2025-03-19 | Filing | |
| $2.09 | 400,000 | $837,160.00 | 3,817,839 | 2025-03-19 | Filing | |
| $2.00 | 2,000,000 | $4,000,800.00 | 4,217,839 | 2025-03-19 | Filing | |
| $2.31 | 1,000,000 | $2,308,100.00 | 6,217,839 | 2025-03-19 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,301,664 | $2,772,069 | 0% | |
| 2. | 564,838 | $1,203,105 | 0% | |
| 3. | 189,148 | $402,886 | 0% | |
| 4. | 165,333 | $352,159 | 0.01% | |
| 5. | 42,795 | $91,153 | 0% |
News See All
Top 10 Stocks Under $5 That Could Triple
At one end of the spectrum, until a few weeks ago, there was optimism about the broader market's performance this year.
Black Diamond Therapeutics, Inc. (BDTX) Price Target Trimmed as Piper Updates Biotech Models and 2026 Catalyst Tracker
TheFly reported on January 16 that Piper Sandler lowered the price target for BDTX to $8 from $9 and maintained an Overweight rating. The change coincided with the company’s revision of several ...
20 Best Biotech Stocks Under $20 to Buy Now
The U.S. biotechnology market enters 2026 as the largest global biotech market, with an estimated size of $552.39 billion in 2023, and is projected to grow to $1.24 trillion by 2030.
Black Diamond Therapeutics’ Silevertinib Shows 60% Response Rate in Preliminary Phase 2 Lung Cancer Data
Black Diamond Therapeutics Inc. (NASDAQ:BDTX) is one of the best biotech penny stocks to buy according to analysts.
10 Best Biotech Penny Stocks to Buy According to Analysts
On December 24, Jared Holz of Mizuho joined 'Power Lunch' on CNBC to talk about how to play biotech moving into 2026.
Guggenheim Sets $8 Price Target as Black Diamond Therapeutics, Inc. (BDTX) Prepares Phase 2 Results
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) is among the best stocks with the highest upside potential. Guggenheim assumed coverage on Black Diamond Therapeutics, Inc.
10 Best Stocks with the Highest Upside Potential
The saying that “what is big today once began as something small” isn’t something new.
Black Diamond Therapeutics, Inc. (BDTX) Rated Outperform as Lead Drug Shows Promise
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) is among the best get rich quick stocks to buy now. Analysts at Raymond James have reinitiated coverage on Black Diamond Therapeutics, Inc.
10 Best Get Rich Quick Stocks to Buy Now
Everyone’s looking for that one big break, whether in their jobs or the stock market.
Hedge Fund Resource Center